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Abstract Prolactin (PRL) has been implicated as a modulator
of immune function, and some of its actions may be linked to
NO synthesis. Because NO acts as a mediator of in£ammation,
we speculated that an in£ammatory milieu could unmask path-
ways by which PRL could a¡ect NO synthesis. Here, we show
that pro-in£ammatory cytokines induce the expression of PRL
receptors in pulmonary ¢broblasts, allowing PRL to inhibit cy-
tokine-induced NO production and the expression of the induc-
ible nitric oxide synthase (iNOS). Inhibition of iNOS expres-
sion by PRL correlates with the phosphorylation of STAT-5b
(signal transducer and activator of transcription 5b) and the
suppression of expression of IRF-1 (interferon regulatory factor
1), a transcription factor for iNOS. These results reveal previ-
ously unrecognized mechanisms by which PRL and PRL recep-
tors may play signi¢cant modulatory roles during immune^in-
£ammatory processes.
0 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
NO is a gaseous biological mediator with e¡ects on smooth
muscle relaxation, neurotransmission, host defense, immunity
and in£ammation [1^3]. NO produced by inducible nitric ox-
ide synthase (iNOS) plays critical roles in modulating in£am-
mation and responses to infectious and degenerative diseases
[3]. iNOS expression is induced by a variety of immunologic
and in£ammatory stimuli, including pro-in£ammatory cyto-
kines (e.g. interleukin 1L [IL-1L], tumor necrosis factor K
[TNFK], interferon Q [IFNQ]) and lipopolysaccharides.
Prolactin (PRL) acts as a circulating hormone and as a
cytokine, eliciting a wide variety of actions [4]. Moreover,
PRL can be proteolytically cleaved to generate 16K PRL, a
PRL fragment with potent anti-angiogenic properties [5,6].
We have recently shown that 16K PRL stimulates iNOS ex-
pression and NO production by rat pulmonary ¢broblasts [7],
resembling the action of pro-in£ammatory cytokines. Unlike
16K PRL and consistent with undetectable PRL receptors,
PRL showed no e¡ect on either iNOS expression or NO syn-
thesis in these pulmonary cells [7]. Since NO acts as a medi-
ator of in£ammation, we speculated that an in£ammatory
milieu could uncover PRL actions on iNOS expression in
pulmonary ¢broblasts, which are important cells in in£amma-
tory reactions of the lung. Here, we investigate the e¡ects of
PRL on NO production and iNOS expression in pulmonary
¢broblasts treated with a combination of pro-in£ammatory
cytokines (IL-1L, TNFK and IFNQ), and we analyze the re-
ceptors and signal transduction pathways involved. Our ¢nd-
ings reveal previously unrecognized anti-in£ammatory proper-
ties of PRL.
2. Materials and methods
2.1. Reagents
Rat pituitary PRL was from the National Hormone and Pituitary
Program (NHPP). Recombinant murine IL-1L, IFNQ, TNFK, trans-
forming growth factor L (TGFL), angiotensin II (Ang II) and platelet-
derived growth factor (PDGF) were from RpD Systems (Minneap-
olis, MN, USA). IRF-1 (interferon regulatory factor 1) cDNA and
anti-STAT-5b (signal transducer and activator of transcription 5b)
rabbit polyclonal antibody were kindly provided by L.-Y. Yu-Lee
(Baylor College of Medicine, Houston, TX, USA) [8], and anti-phos-
photyrosine (anti-pY) monoclonal antibody was a gift of C. Rosales
(UNAM, Mexico City, Mexico) [9].
2.2. Cell culture
Rat pulmonary ¢broblasts were isolated from Sprague^Dawley rat
fetuses as previously described [10]. Cells were grown in Ham’s F-12
medium with 10% heat-inactivated fetal bovine serum (HI FBS), and
experiments were performed in Ham’s F12 containing 0.5% HI FBS.
Unless otherwise stated, for all experiments ¢broblasts were pre-
treated for 6 h with 2.5 ng/ml IL-1L, 50 U/ml IFNQ and 12.5 ng/ml
TNFK and further incubated with 10 nM rat PRL for 24 h.
2.3. Reverse-transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA,
USA) and treated with RNase-free DNase for 15 min at 37‡C fol-
lowed by phenol^chloroform extraction. Reverse transcription was
performed using 5 Wg of total RNA, 5 WM oligo(dT)16 primers, and
MMLV retrotranscriptase (Invitrogen) at 37‡C for 1 h. For PRL
receptors, a common forward primer (5P-ATCCTGGGCAGATGG-
AGGAC-3P) and a common reverse primer (5P-ATCCACACGGTT-
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GTGTCCTTC-3P) were used to detect the short, intermediate and
long isoforms. Reverse primers that speci¢cally detect the short (5P-
TGGCTGAGGCTGACAAAAGAG-3P) or long (5P-AGACAGTG-
GGGCTTTTCTCCT-3P) isoform were also used. For iNOS detection,
the forward primer 5P-GTGTTCCACCAGGAGATGTTG-3P and the
reverse primer 5P-CTCCTGCCCACTGAGTT CGTC-3P were em-
ployed. Messenger RNAs for ribosomal protein L19 (RPL19) and
glucose-6-phosphate dehydrogenase (G6PDH) were ampli¢ed as inter-
nal controls. For RPL19, forward and reverse primers were 5P-
CGAAATCGCCAATGCCAACTC-3P and 5P-TGCTCCATGAGAA-
TCCGCTTG-3P, respectively. For G6PDH, forward primer 5P-GA-
CCTGCAGAGCTCCAATCAAC-3P and reverse primer 5P-CACGA-
CCCTCAGTACCAAAGGG-3P were used. Conventional PCR was
performed as previously described [11], using 40 cycles for iNOS
and PRL receptors, and 21 cycles for RPL19 and G6PDH. Real-
time PCR was carried out using RPL19 or G6PDH as internal stan-
dards, in reactions that contained 1 Wl aliquots of the reverse tran-
scription reaction described above, 7.5 Wl of quantitect SYBR Green
PCR (Qiagen, Hilden, Germany) and 400 nM forward and reverse
primers in 15 Wl total volume. Detection and data analyses were car-
ried out on a LightCycler Instrument according to the manufacturer’s
instructions (Roche Molecular Biochemicals, Mannheim, Germany).
2.4. Nitrite and nitrate assay
The oxidation products of cNO, nitrite (NO32 ) and nitrate (NO
3
3 )
were determined in cell culture media by the Greiss reaction as pre-
viously described [12].
2.5. Western blot and immunoprecipitation
To determine the tyrosyl-phosphorylation of STAT-5b, ¢broblasts
were pre-treated with cytokines for 6 h and incubated in the absence
or presence of 10 nM PRL for 30 min. A combination of immuno-
precipitation and Western blot analyses was performed as previously
described [13]. Brie£y, cells were lysed in RIPA bu¡er (50 mM Tris
pH 7.4, 0.5% NP-40, 0.2% sodium deoxycholate, 100 mM NaCl, 1 mM
EGTA, 1 mM phenylmethylsulfonyl £uoride, 1 Wg/ml aprotinin, 1 mM
sodium orthovanadate, and 1 mM NaF). Lysates were centrifuged
and pre-cleared with protein-A beads for 1 h, then incubated with
anti-STAT-5b antibody (2 Wg/ml) overnight. 60 Wl of protein-A beads
was added, and the immunoprecipitated proteins were resolved on
7.5% SDS^PAGE. Membranes were probed with anti-pY antibodies
(5 Wg/ml) and re-probed with anti-STAT-5b (2 Wg/ml) antibodies.
2.6. Northern blot
To detect IRF-1 mRNA, 10 Wg of RNA extracted from ¢broblasts
was denatured and electrophoresed in a denaturing formaldehyde/1%
agarose gel. Northern blotting was performed using a 1.5 kb fragment
of a speci¢c cDNA probe for rat IRF-1 labeled with [K-32P]dCTP
(Amersham Biosciences, Piscataway, NJ, USA). The blots were re-
probed with 32P-RPL19 cDNA as an internal standard for RNA
loading.
2.7. Statistical analysis
All results were replicated in three or more independent experi-
ments. Data are expressed as meanTS.E.M. Statistical analysis was
performed by the unpaired Student’s t-test. PH0.05 was considered
statistically signi¢cant.
3. Results and discussion
Based on the hypothesis that an in£ammatory milieu would
unmask PRL actions on NO synthesis, we analyzed PRL
e¡ects on NO production by resting versus cytokine-stimu-
lated pulmonary ¢broblasts (Fig. 1A). Consistent with pre-
vious observations [7], PRL did not modify basal NO levels
in the untreated cells (lower curve). However, in cells pre-
treated with a mixture of IL-1L, TNFK and IFNQ, known
to act synergistically to stimulate NO production [12], PRL
produced a signi¢cant (PH0.05) inhibition of NO synthesis in
a dose-dependent manner (upper curve, Fig. 1A). Inhibition
by PRL was similar to e¡ective doses of TGFL (0.4^10 nM),
Ang II (10 nM) and PDGF (0.4^10 nM), three known inhib-
itors of cytokine-induced NO [14^16] (Fig. 1B). Finally, PRL
inhibition was not restricted to rat pulmonary cells, as it also
occurred in the A549 human lung epithelial cell line; however,
rat aortic smooth muscle cells were not a¡ected (Fig. 1C).
Consistent with the inhibition of NO production, conven-
tional and real-time RT-PCR showed that PRL signi¢cantly
decreased (PH0.05) cytokine-induced iNOS expression, but
not basal expression (Fig. 2). While cytokines induced a 16-
fold increase in iNOS mRNA, PRL decreased the cytokine
e¡ect four-fold (Fig. 2B). However, the magnitude of the re-
duction of iNOS mRNA did not correlate well with that of
Fig. 1. A: PRL inhibits cytokine-induced NO production in a dose-
dependent manner in rat pulmonary ¢broblasts. B: Comparative ef-
fect of PRL (10 nM), TGFL (0.4 nM), Ang II (10 nM) and PDGF
(0.4 nM) on cytokine-induced NO production by rat pulmonary ¢-
broblasts. C: PRL e¡ect on cytokine-induced NO production by rat
pulmonary ¢broblasts, A549 human lung epithelial cells and rat
aortic smooth muscle cells (RASMC). For all experiments, cells
were pre-treated for 6 h with or without cytokines (2.5 ng/ml IL-1L,
50 U/ml IFNQ and 12.5 ng/ml TNFK) and further incubated with
PRL (10 nM), TGFL, Ang II or PDGF for 24 h. NO production
was measured by accumulation of NO32 +NO
3
3 in the culture me-
dium. Values are the meanTS.E.M. *PH0.05 versus cytokines alone
(Cyt).
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NO (Fig. 1). The reason for this di¡erence is unclear but may
re£ect the fact that the NO measured represents the accumu-
lation of stable NO metabolites over time, whereas iNOS
mRNA can have a short, 1 h half-life [17], and its values
re£ect a point in time after PRL treatment.
We previously showed that the expression of PRL receptors
in resting ¢broblasts is undetectable [7] ; however, here we
show that PRL is able to inhibit cytokine-induced iNOS ex-
pression and NO production in the same cell type. Hence, we
hypothesized that the cytokines used to induce iNOS also
induce the expression of PRL receptors that in turn could
mediate PRL action. To address this possibility, we investi-
gated the expression of PRL receptors in cytokine-treated
cells. While PRL receptors were not detected in control ¢bro-
blasts, either in the absence or presence of PRL, the expres-
sion of the long PRL receptor isoform was markedly induced
by cytokine treatment (Fig. 3). The mRNA for the short PRL
receptor was not detectable. In support of these ¢ndings, anal-
ysis by real-time PCR showed an approximately six-fold in-
duction of the long PRL receptor by cytokine treatment, both
in the absence and presence of PRL (Fig. 3B). Therefore, the
combination of IL-1L, TNFK and IFNQ acts to promote the
expression of PRL receptors in pulmonary ¢broblasts, en-
abling PRL to inhibit cytokine-induced iNOS expression.
To characterize the mechanisms underlying PRL e¡ects on
iNOS expression, the activation of the classical signal trans-
duction pathway associated with the PRL receptor was inves-
tigated. The interaction of PRL with its receptor leads to the
downstream phosphorylation of STAT factors, primarily
STAT-5 or STAT-1 [4]. Phosphorylated STAT-5 or STAT-1
homo-dimerize and translocate to the nucleus, where they
regulate the transcription of speci¢c genes, including IRF-1
[18]. While STAT-1 can activate IRF-1 [13,19], STAT-5 can
inhibit IRF-1 transcription [8,20,21]. In fact, IRF-1 is one of
the transcription factors that activates the iNOS promoter
[22,23]. Here, we investigated the extent of phosphorylation
of the STAT-5b protein and the levels of IRF-1 mRNA in
¢broblasts treated with PRL. Consistent with the absence of
functional PRL receptors, treatment with PRL alone did not
increase STAT-5b phosphorylation (Fig. 4A); however, after
cytokine treatment, PRL stimulated STAT-5b phosphoryla-
tion, when compared with control cells or cells treated with
cytokines alone (Fig. 4A). These results suggest that after
cytokine treatment, pulmonary ¢broblasts express functional
PRL receptors and become responsive to PRL signaling as
determined by STAT-5b tyrosine phosphorylation. Further-
more, PRL inhibited cytokine-induced IRF-1 expression
(Fig. 4B). While similar basal levels of IRF-1 mRNA were
observed in the absence of cytokines, a clear induction of
IRF-1 was observed after cytokine treatment (Fig. 4B). This
result was expected since IFNQ is known to induce IRF-1 [22].
Remarkably, PRL was able to counteract the e¡ect of the
cytokine treatment by reducing IRF-1 mRNA levels (Fig.
Fig. 2. PRL inhibits cytokine-induced iNOS expression in rat pul-
monary ¢broblasts. A: iNOS mRNA was analyzed by RT-PCR per-
formed on total RNA extracted from cells. Ampli¢cation of RPL19
is shown as control. B: Quantitation of iNOS mRNA expression us-
ing real-time PCR. Cells were pre-treated for 6 h with or without
cytokines (2.5 ng/ml IL-1L, 50 U/ml IFNQ and 12.5 ng/ml TNFK),
and then incubated in the absence or presence of 10 nM PRL for
24 h. *PH0.05 versus cytokines alone (Cyt).
Fig. 3. Pro-in£ammatory cytokines induce the expression of the
long PRL receptor in rat pulmonary ¢broblasts. A: The mRNA for
the long PRL receptor was analyzed by RT-PCR performed on to-
tal RNA. Ampli¢cation of G6PDH is shown as control. B: Quanti-
tation of mRNA for the long PRL receptor using real-time PCR.
Cells were pre-treated for 6 h with or without cytokines (2.5 ng/ml
IL-1L, 50 U/ml IFNQ and 12.5 ng/ml TNFK) and then incubated
for 24 h in the absence or presence of 10 nM PRL. For both ¢g-
ures: untreated control cells (C), PRL alone (PRL), cytokines alone
(Cyt) and cells pre-treated with cytokines and further incubated
with PRL (Cyt+PRL). *PH0.05 versus basal and PRL-treated con-
trols.
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4B). These results show for the ¢rst time in a non-genetically
modi¢ed primary culture cell type that PRL acts to induce
STAT-5b activation and to inhibit the expression of IRF-1.
Because IRF-1 is one of the transcription factors required for
iNOS expression [22,23], PRL inhibition of IRF-1 could ex-
plain the downstream PRL inhibitory e¡ect on iNOS mRNA
observed in ¢broblasts. These ¢ndings agree with a previously
proposed mechanism by which phosphorylated STAT-5b can
inhibit the induction of the IRF-1 via protein^protein inter-
actions and competition for limiting transcriptional co-activa-
tors [8,21].
In conclusion, our results demonstrate that PRL acts to
inhibit cytokine-induced iNOS expression and NO production
by rat pulmonary ¢broblasts. The PRL e¡ect appears to be
mediated by cytokine-induced PRL receptors, which upon
activation lead to the phosphorylation of STAT-5b and the
inhibition of IRF-1 expression. To our knowledge, the present
¢ndings represent the ¢rst evidence in which up-regulation of
the PRL receptor occurs in response to pro-in£ammatory cy-
tokines and is a requirement for any PRL action.
The PRL inhibitory e¡ect on cytokine-induced NO produc-
tion and iNOS expression occurs in pulmonary cells (¢bro-
blasts and epithelial) from di¡erent species (rat and human)
but not in other cell types (rat smooth muscle cells). These
¢ndings suggest that the lung is a site for the anti-in£amma-
tory e¡ect of PRL. However, in other cells PRL can activate
NO synthesis. Previous investigations have shown that PRL
elevates NO production in mouse macrophages [24] and in-
duces iNOS expression in human leukocytes [25] and in rat C6
glioma cells [26]. Opposite e¡ects are not unexpected since the
regulation of iNOS expression is complex and known to be
cell- and species-speci¢c [27]. For example, regulatory factors,
such as retinoic acid and TGFL, can either inhibit [28^30] or
potentiate [31^33] iNOS expression, depending on the cell
type investigated.
This study, together with our previous work [7], reveals that
PRL and 16K PRL have dichotomous e¡ects on NO produc-
tion by rat pulmonary ¢broblasts. While 16K PRL acts as a
pro-in£ammatory cytokine inducing the expression of iNOS
in resting conditions, PRL acts as an anti-in£ammatory fac-
tor, attenuating the cytokine-induced iNOS expression. The
fact that pro-in£ammatory cytokines induced the expression
of PRL receptors further supports the idea that the inhibitory
e¡ect of PRL is secondary to the action of pro-in£ammatory
cytokines, and it suggests that relevant PRL functions may
become apparent during the in£ammatory process. Because
NO acts as a mediator of in£ammation [3], the outcome of
the hormonal e¡ect could promote or inhibit the in£amma-
tory response, depending on the activity of the proteases re-
sponsible for processing PRL into 16K PRL and on the se-
lective expression of the receptors for each PRL isoform.
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